摘要
背景:糖结合蛋白广泛分布于人类体内,在生物过程中起着至关重要的作用.他们在炎症和免疫反应中的参与使其变得越来越像甘氨酸结合蛋白可能是有价值的治疗靶点。目的:本综述旨在提供抗体临床进展的最新资料。作为潜在靶点的糖结合蛋白。 结果与结论:目前已开发出多种针对不同疾病的治疗性抗体,包括CD22、CD33、DEC-205和CD62P。临床投资免疫测定显示了一种抗CD 22抗体药物结合治疗的益处,并得到了监管机构的批准。这些抗体的临床研究进展为治疗多种疾病(包括炎症、自身免疫性疾病和血液恶性肿瘤)提供了良好的治疗靶点。
关键词: 甘氨酸结合蛋白,凝集素,抗体,临床发育,炎症,自身免疫性疾病,血液学 malignance恶意,有害
图形摘要
Current Drug Targets
Title:Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Volume: 19 Issue: 13
关键词: 甘氨酸结合蛋白,凝集素,抗体,临床发育,炎症,自身免疫性疾病,血液学 malignance恶意,有害
摘要: Background: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.
Objective: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets.
Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.
Export Options
About this article
Cite this article as:
Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450119666180308144313
DOI https://dx.doi.org/10.2174/1389450119666180308144313 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Current Molecular Medicine Controlled-release Particulate Cytokine Adjuvants for Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews Anti-Cancer Potential of a Novel SERM Ormeloxifene
Current Medicinal Chemistry Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets Human Multidrug Transporter ABCG2, a Target for Sensitizing Drug Resistance in Cancer Chemotherapy
Current Medicinal Chemistry Parallel Gene Expression Profiling of Mantle Cell Lymphoma – How Do We Transform ´Omics Data into Clinical Practice
Current Genomics Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential
Current Genomics Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Therapeutic Targeting of Melanoma Cells Using Neural Stem Cells Expressing Carboxylesterase, a CPT-11 Activating Enzyme
Current Stem Cell Research & Therapy